acetylleucyl-leucyl-norleucinal has been researched along with rupintrivir in 1 studies
| Studies (acetylleucyl-leucyl-norleucinal) | Trials (acetylleucyl-leucyl-norleucinal) | Recent Studies (post-2010) (acetylleucyl-leucyl-norleucinal) | Studies (rupintrivir) | Trials (rupintrivir) | Recent Studies (post-2010) (rupintrivir) |
|---|---|---|---|---|---|
| 321 | 0 | 53 | 69 | 2 | 42 |
| Protein | Taxonomy | acetylleucyl-leucyl-norleucinal (IC50) | rupintrivir (IC50) |
|---|---|---|---|
| Genome polyprotein | Human rhinovirus sp. | 0.023 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amin, SA; Banerjee, S; Gayen, S; Ghosh, K; Jha, T | 1 |
1 review(s) available for acetylleucyl-leucyl-norleucinal and rupintrivir
| Article | Year |
|---|---|
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
Topics: Antiviral Agents; Catalytic Domain; Coronavirus 3C Proteases; Cysteine Proteinase Inhibitors; Drug Discovery; Drug Evaluation, Preclinical; Molecular Docking Simulation; Molecular Structure; Protein Binding; Quantitative Structure-Activity Relationship; SARS-CoV-2 | 2021 |